Please login to the form below

Not currently logged in
Email:
Password:

GSK Biologicals signs Alzheimer's deal with AFFiRiS

GlaxoSmithKline's (GSK) vaccine division has acquired exclusive rights to develop and commercialise two Alzheimer's vaccine candidates

GlaxoSmithKline's (GSK) vaccine division has acquired exclusive rights to develop and commercialise two Alzheimer's vaccine candidates.

The vaccines, which are currently under Phase I clinical development, are being developed using the AFFiRiS' AFFiTOPE technology. This allows the development of proteins that bind to the disease-causing human proteins that are central to the pathology of Alzheimer's disease.

Jean Stephenne, president and general manager of GlaxoSmithKline Biologicals said: "We are impressed with the AFFiRiS technology - combined with our expertise in innovative adjuvant systems this collaboration will improve our chance of success in the discovery of new treatments against this major disease."

The deal will see AFFiRIS receive an up-front payment of £17.5m with the possibility of future milestone and royalty payments. In the event of the vaccines reaching full commercial success and gaining government authority approval, the value of the agreement could reach £334m.

23rd October 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics